← Back to Search

Behavioural Intervention

Social Prescribing for Heart Failure

N/A

Waitlist Available

Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

18 years of age or older

Documented HF of any etiology

Must not have

Do not take HF medications

Patients with severe cognitive impairment or other conditions that significantly impact the ability to participate in SP will also be excluded.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6- 12 months

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to see if a new approach called social prescribing can help improve medication adherence and quality of life in Canadian women with heart failure. Social prescribing involves personalized referrals to non-medical supports or services

Who is the study for?

This trial is for Canadian women with heart failure who are at high risk of not following their medical treatment plans. They must score two or more points on a social health questionnaire and be willing to potentially receive non-medical support based on their needs.

What is being tested?

The study tests if 'Social Prescribing' (SP), which involves personalized referrals to community services, can help these women follow their heart medication schedules better and improve their quality of life compared to standard care without SP.

What are the potential side effects?

Since Social Prescribing is a non-medical intervention focusing on addressing social needs rather than direct medical treatments, it does not have typical side effects like medications do.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I have been diagnosed with heart failure.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I do not take heart failure medications.

Select...

I do not have severe cognitive impairment or conditions that prevent me from participating in study procedures.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6- 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6- 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6- 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Proportion of days

Secondary study objectives

KCCQ overall score

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Social prescriptionExperimental Treatment1 Intervention

The intervention consists of SP, wherein patients identified as having significant SDOH-related vulnerabilities on the SPARK questionnaire or during an interview will have a consultation with a LW who will provide them with social prescriptions.

Group II: ControlActive Control1 Intervention

Usual Care

0 / 4Eligibility criteria met